<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Preclinical Evaluation of a Novel CAR T Therapy using Champions' DLBCL PDX Models

A Champions Case Study

Chimeric Antigen Receptor (CAR) T cell therapies have revolutionized the therapeutic management of hematological malignancies and hold great promise for solid tumors. 

Diffuse Large B Cell Lymphoma (DLBCL) is a cancer of B cells and is the most common form of non-Hodgkin's Lymphoma (NHL) among adults. 

In this case study, we review the preclinical evaluation of a novel CAR T therapy in our rare DLBCL PDX models.  

Download the Case Study